Tag: genomic cancer panel and profiling market analysis

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Genomic Cancer Panel And Profiling Market Forecast: Value Set To Climb From $11.17 Billion To $15.44 Billion

The genomic cancer panel and profiling market size has demonstrated robust growth in recent years. It will grow from $10.28 billion in 2025 to $11.17 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. This historical expansion is primarily attributable to factors such as an increase in cancer prevalence, progress in sequencing technologies, the broadening of oncology diagnostics, enhanced funding for genomic research, and the escalating adoption of precision medicine.

The genomic cancer panel and profiling market is anticipated to experience substantial growth over the coming years. Projections indicate it will reach $15.45 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.4%. This expansion during the forecast period is driven by factors such as the increasing use of companion diagnostics, the rising adoption of liquid biopsy, the incorporation of AI into genomic analysis, the proliferation of oncology screening programs, and the creation of more affordable sequencing platforms. Key developments expected in this period include the wider acceptance of multi-gene cancer panels, the growing application of next-generation sequencing, the broadening of liquid biopsy testing, the escalating need for personalized oncology solutions, and the seamless integration of genomic data into clinical decision-making processes.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=41197447&type=smp&name=Genomic%20Cancer%20Panel%20And%20Profiling%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Genomic Cancer Panel And Profiling Market Growth Momentum: What Factors Are Shaping Demand?

The genomic cancer panel and profiling market is projected to expand in the future due to an increasing incidence of cancer. Cancer is a disease characterized by the uncontrolled proliferation and dissemination of abnormal cells throughout the body. The rise in cancer cases is attributable to an aging global population, where a longer life expectancy correlates with an elevated probability of developing cancer. Genomic cancer panels and profiling are instrumental in oncology care by identifying genetic mutations and biomarkers, facilitating personalized treatment strategies, and enhancing early detection and monitoring. For instance, in January 2024, according to the American Cancer Society, a U.S.-based nonprofit organization, around 20 million new cancer cases were reported globally in 2022, resulting in 9.7 million deaths; primarily driven by population growth, the global cancer burden is forecasted to increase to 35 million cases by 2050. Therefore, the growing incidence of cancer will stimulate the growth of the genomic cancer panel and profiling market.

Genomic Cancer Panel And Profiling Market Segmentation And Category Overview

The genomic cancer panel and profiling market covered in this report is segmented –

1) By Tissue Testing: Solid Tissue Testing, Liquid Tissue Testing

2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Other Technologies

3) By Cancer Panel Type: Single-Gene Panel, Multi-Gene Panel

4) By Application: Clinical, Research

5) By End User: Hospitals, Research And Academic Institutes, Clinical And Diagnostic Laboratories, Other End Users

Subsegments:

1) By Solid Tissue Testing: Biopsy Samples, Surgical Resection Samples, Formalin-Fixed Paraffin-Embedded (FFPE) Tissues, Fresh Frozen Tissues

2) By Liquid Tissue Testing: Blood, Urine, Saliva, Cerebrospinal Fluid (CSF), Other Bodily Fluids

Genomic Cancer Panel And Profiling Market Trends Redefining Industry Growth

Leading firms within the genomic cancer panel and profiling market are prioritizing innovations such as next-generation sequencers to enhance the accuracy, speed, and comprehensiveness of cancer diagnostics, thereby facilitating more personalized treatment decisions. Next-generation sequencers represent sophisticated DNA sequencing methods that allow for swift and extensive examination of genetic material for pinpointing mutations, variations, and other genomic features. For instance, in April 2025, QIAGEN N.V., a Netherlands-based biotechnology company, introduced QIAseq panels tailored for use with next-generation sequencers, which facilitate thorough genomic profiling through the analysis of over 700 genes. These panels serve both research and clinical applications, with the objective of enhancing cancer diagnostics and treatment strategies.

Genomic Cancer Panel And Profiling Market Competitive Analysis Of Leading Industry Participants

Major companies operating in the genomic cancer panel and profiling market are Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Hologic Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, ARUP Laboratories, Tempus Labs, Genscript Biotech Corporation, NeoGenomics Inc., Foundation Medicine, Invitae Corporation, Guardant Health Inc., Caris Life Sciences, Fulgent Genetics, NanoString Technologies Inc., Genecast Biotechnology Co. Ltd, Burning Rock DX, HTG Molecular Diagnostics Inc., Predictive Oncology Inc.

View The Full Genomic Cancer Panel And Profiling Market Report:

https://thebusinessresearchcompany.com/report/genomic-cancer-panel-and-profiling-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Genomic Cancer Panel And Profiling Market Regional Analysis: Which Geography Leads On Revenue?

North America was the largest region in the genomic cancer panel and profiling market in 2025. The regions covered in the genomic cancer panel and profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Genomic Cancer Panel And Profiling Market Size Forecast: How Large Could The Market Become By 2030?

The market for genomic cancer panels and profiling has experienced significant expansion in recent years. Valued at $10.28 billion in 2025, it is projected to reach $11.17 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.7%. This historic growth has been fueled by increasing cancer incidence, progress in sequencing technologies, broader oncology diagnostic applications, greater investment in genomic research, and a growing embrace of precision medicine.

Strong expansion is anticipated for the genomic cancer panel and profiling sector over the coming years. By 2030, its value is projected to reach $15.45 billion, progressing at a compound annual growth rate (CAGR) of 8.4%. This forecasted growth is driven by several factors, including the broadening scope of companion diagnostics, a rising uptake of liquid biopsy methods, the incorporation of artificial intelligence into genomic analysis, the growth of oncology screening efforts, and the emergence of more affordable sequencing technologies. Key developments shaping this period are a greater preference for multi-gene cancer panels, the widespread application of next-generation sequencing, the broadening of liquid biopsy use, heightened interest in personalized cancer treatments, and the incorporation of genomic data into clinical decision-making.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24225&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Genomic Cancer Panel And Profiling Market Demand Drivers Creating New Revenue Opportunities

Rising rates of cancer diagnoses are expected to fuel the expansion of the genomic cancer panel and profiling market in the coming years. Cancer is defined by the abnormal and uncontrolled proliferation of cells within the body. This increase in cancer cases is linked to an aging global population, as longer life expectancy heightens the likelihood of developing the disease. Genomic cancer panels and profiling support oncology practices by detecting genetic mutations and biomarkers, enabling tailored treatment plans, and enhancing early detection and ongoing monitoring. As an example, in January 2024, the American Cancer Society, a U.S.-based nonprofit organization, reported that around 20 million new cancer cases were documented worldwide in 2022, leading to 9.7 million deaths; primarily due to population growth, the global cancer burden is expected to climb to 35 million cases by 2050. Consequently, the rising number of cancer diagnoses will drive the growth of the genomic cancer panel and profiling market.

Genomic Cancer Panel And Profiling Market Segment Analysis And Revenue Opportunities

The genomic cancer panel and profiling market covered in this report is segmented –

1) By Tissue Testing: Solid Tissue Testing, Liquid Tissue Testing

2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Other Technologies

3) By Cancer Panel Type: Single-Gene Panel, Multi-Gene Panel

4) By Application: Clinical, Research

5) By End User: Hospitals, Research And Academic Institutes, Clinical And Diagnostic Laboratories, Other End Users

Subsegments:

1) By Solid Tissue Testing: Biopsy Samples, Surgical Resection Samples, Formalin-Fixed Paraffin-Embedded (FFPE) Tissues, Fresh Frozen Tissues

2) By Liquid Tissue Testing: Blood, Urine, Saliva, Cerebrospinal Fluid (CSF), Other Bodily Fluids

Genomic Cancer Panel And Profiling Market Trends Driving Strategic Industry Expansion

Key industry players within the genomic cancer panel and profiling market are increasingly investing in technological innovations, particularly next-generation sequencers, to enhance the precision, efficiency, and breadth of cancer diagnostics, ultimately supporting more tailored therapeutic decisions. These sequencers represent sophisticated DNA analysis tools capable of rapid, high-volume evaluation of genetic material, detecting mutations, variations, and other genomic markers. A notable example occurred in April 2025, when QIAGEN N.V., a biotechnology firm based in the Netherlands, introduced its QIAseq panels specifically for use with next-generation sequencers. These panels allow comprehensive genomic profiling by examining over 700 genes, designed to serve both research and clinical settings with the goal of advancing cancer detection and treatment planning.

Genomic Cancer Panel And Profiling Market Leading Players Shaping Industry Direction

Major companies operating in the genomic cancer panel and profiling market are Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Hologic Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, ARUP Laboratories, Tempus Labs, Genscript Biotech Corporation, NeoGenomics Inc., Foundation Medicine, Invitae Corporation, Guardant Health Inc., Caris Life Sciences, Fulgent Genetics, NanoString Technologies Inc., Genecast Biotechnology Co. Ltd, Burning Rock DX, HTG Molecular Diagnostics Inc., Predictive Oncology Inc.

Access The Complete Genomic Cancer Panel And Profiling Market Report:

https://www.thebusinessresearchcompany.com/report/genomic-cancer-panel-and-profiling-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Genomic Cancer Panel And Profiling Market Regional Analysis And Leading Geography

North America was the largest region in the genomic cancer panel and profiling market in 2025. The regions covered in the genomic cancer panel and profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Much Larger Will The Genomic Cancer Panel And Profiling Market Become By 2030 Compared To 2026?

The genomic cancer panel and profiling market has experienced substantial expansion in recent times. Its value is expected to rise from $10.28 billion in 2025 to $11.17 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.7%. The market’s previous growth phases are linked to an uptick in cancer prevalence, developments in sequencing technologies, the widening scope of oncology diagnostics, augmented funding for genomic research, and the increasing utilization of precision medicine.

The genomic cancer panel and profiling market is anticipated to experience substantial expansion over the coming years. Its valuation is projected to reach $15.45 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.4%. This projected increase during the forecast period is driven by factors such as the wider application of companion diagnostics, the growing acceptance of liquid biopsy, the incorporation of AI into genomic analysis, the rise in oncology screening initiatives, and the creation of more economical sequencing platforms. Key developments foreseen for this period include the increased uptake of multi-gene cancer panels, the greater utilization of next-generation sequencing, the broadening scope of liquid biopsy testing, the rising need for personalized oncology solutions, and the incorporation of genomic information into clinical decision-making processes.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24225&type=smp

What Important Drivers Are Powering The Genomic Cancer Panel And Profiling Market Growth?

The escalating occurrence of cancer is anticipated to propel the expansion of the genomic cancer panel and profiling market moving forward. Cancer is characterized as a condition involving the uncontrolled proliferation and dissemination of abnormal cells within the body. This increase in cancer incidence is attributed to an aging global population, which elevates the risk of developing cancer as life expectancy continues to rise. Genomic cancer panels and profiling contribute to oncology care by identifying genetic mutations and biomarkers, thereby enabling personalized treatment strategies and enhancing early detection and monitoring. For example, in January 2024, the American Cancer Society, a U.S.-based nonprofit organization, reported that in 2022, approximately 20 million new cancer cases were identified globally, resulting in 9.7 million deaths. Primarily driven by population growth, the global cancer burden is projected to reach 35 million cases by 2050. Consequently, the increasing incidence of cancer will significantly drive the growth of the genomic cancer panel and profiling market.

What Segment Types Are Included In The Genomic Cancer Panel And Profiling Market Analysis?

The genomic cancer panel and profiling market covered in this report is segmented –

1) By Tissue Testing: Solid Tissue Testing, Liquid Tissue Testing

2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Other Technologies

3) By Cancer Panel Type: Single-Gene Panel, Multi-Gene Panel

4) By Application: Clinical, Research

5) By End User: Hospitals, Research And Academic Institutes, Clinical And Diagnostic Laboratories, Other End Users

Subsegments:

1) By Solid Tissue Testing: Biopsy Samples, Surgical Resection Samples, Formalin-Fixed Paraffin-Embedded (FFPE) Tissues, Fresh Frozen Tissues

2) By Liquid Tissue Testing: Blood, Urine, Saliva, Cerebrospinal Fluid (CSF), Other Bodily Fluids

Which Trends Are Expected To Shape The Genomic Cancer Panel And Profiling Market?

Major corporations operating in the genomic cancer panel and profiling market are prioritizing technological advancements, such as next-generation sequencers, to boost the accuracy, speed, and overall comprehensiveness of cancer diagnostics, thereby enabling more individualized treatment options. Next-generation sequencers are sophisticated DNA sequencing technologies that facilitate rapid, high-throughput examination of genetic material to pinpoint mutations, variations, and other genomic attributes. For instance, in April 2025, QIAGEN N.V., a Netherlands-based biotechnology firm, introduced QIAseq panels, which are designed for next-generation sequencers and allow for comprehensive genomic profiling by analyzing over 700 genes. These panels are intended for both research and clinical applications, with the goal of enhancing cancer diagnostics and treatment strategies.

Which Firms Are Competing In The Genomic Cancer Panel And Profiling Market?

Major companies operating in the genomic cancer panel and profiling market are Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Hologic Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, ARUP Laboratories, Tempus Labs, Genscript Biotech Corporation, NeoGenomics Inc., Foundation Medicine, Invitae Corporation, Guardant Health Inc., Caris Life Sciences, Fulgent Genetics, NanoString Technologies Inc., Genecast Biotechnology Co. Ltd, Burning Rock DX, HTG Molecular Diagnostics Inc., Predictive Oncology Inc.

Access The Complete Genomic Cancer Panel And Profiling Market Report:

https://www.thebusinessresearchcompany.com/report/genomic-cancer-panel-and-profiling-global-market-report

Which Region Stands As The Largest Contributor To The Genomic Cancer Panel And Profiling Market?

North America was the largest region in the genomic cancer panel and profiling market in 2025. The regions covered in the genomic cancer panel and profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Genomic Cancer Panel And Profiling Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24225&type=smp

Browse Through More Reports Similar to the Global Genomic Cancer Panel And Profiling Market 2026, By The Business Research Company

Cancer Profiling Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

Genomics In Cancer Care Market Report 2026

https://www.thebusinessresearchcompany.com/report/genomics-in-cancer-care-global-market-report

Cancer Tumor Profiling Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Genomic Cancer Panel And Profiling Market During 2026–2030?

The genomic cancer panel and profiling market has demonstrated strong growth in recent years. It is anticipated to increase from $10.28 billion in 2025 to $11.17 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.7%. This historical expansion can be attributed to factors such as growth in cancer prevalence, advancement in sequencing technologies, expansion of oncology diagnostics, increased funding for genomic research, and the rising adoption of precision medicine.

The market for genomic cancer panels and profiling is anticipated to experience substantial expansion in the coming years. This market is projected to reach $15.45 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.4%. Key drivers for this growth during the forecast period include the widening application of companion diagnostics, the rising uptake of liquid biopsy, the incorporation of AI into genomic analysis, an increase in oncology screening initiatives, and the creation of more economical sequencing platforms. Significant trends identified for the forecast timeframe encompass the expanding utilization of multi-gene cancer panels, the increasing deployment of next-generation sequencing, the broadening scope of liquid biopsy testing, a heightened need for personalized oncology solutions, and the seamless integration of genomic insights into clinical decision-making processes.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24225&type=smp

What Primary Drivers Are Shaping The Genomic Cancer Panel And Profiling Market?

An escalating incidence of cancer is anticipated to fuel the expansion of the genomic cancer panel and profiling market moving forward. This increase in cancer, a disease marked by the unrestrained proliferation and dissemination of atypical cells within the body, is largely attributable to an aging global populace, which elevates the probability of developing the condition as human longevity extends. Genomic cancer panels and profiling are instrumental in oncology care by identifying specific genetic mutations and biomarkers, thereby facilitating personalized treatment approaches and enhancing capabilities for early detection and ongoing monitoring. For example, in January 2024, the American Cancer Society, a U.S.-based nonprofit organization, reported that in 2022, approximately 20 million new cancer cases were recorded worldwide, resulting in 9.7 million deaths. Primarily driven by demographic growth, the global cancer burden is projected to reach 35 million cases by 2050. Hence, the increasing number of cancer diagnoses will stimulate the growth of the genomic cancer panel and profiling market.

Which Segment Classifications Are Used In The Genomic Cancer Panel And Profiling Market Segment Analysis?

The genomic cancer panel and profiling market covered in this report is segmented –

1) By Tissue Testing: Solid Tissue Testing, Liquid Tissue Testing

2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Other Technologies

3) By Cancer Panel Type: Single-Gene Panel, Multi-Gene Panel

4) By Application: Clinical, Research

5) By End User: Hospitals, Research And Academic Institutes, Clinical And Diagnostic Laboratories, Other End Users

Subsegments:

1) By Solid Tissue Testing: Biopsy Samples, Surgical Resection Samples, Formalin-Fixed Paraffin-Embedded (FFPE) Tissues, Fresh Frozen Tissues

2) By Liquid Tissue Testing: Blood, Urine, Saliva, Cerebrospinal Fluid (CSF), Other Bodily Fluids

Which Trends Are Impacting The Progress Of The Genomic Cancer Panel And Profiling Market?

Leading companies in the genomic cancer panel and profiling market are focusing on technological advancements, such as next-generation sequencers, to improve the precision, speed, and breadth of cancer diagnostics and enable more tailored treatment decisions. Next-generation sequencers represent sophisticated DNA sequencing technologies that allow for rapid, high-throughput analysis of genetic material to identify mutations, variations, and other genomic features. For instance, in April 2025, QIAGEN N.V., a Netherlands-based biotechnology company, launched QIAseq panels specifically designed for next-generation sequencers, facilitating comprehensive genomic profiling by analyzing over 700 genes. These panels are intended for both research and clinical applications, aiming to enhance cancer diagnostics and treatment strategies.

Which Firms Are Contributing To The Genomic Cancer Panel And Profiling Market Ecosystem?

Major companies operating in the genomic cancer panel and profiling market are Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Hologic Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, ARUP Laboratories, Tempus Labs, Genscript Biotech Corporation, NeoGenomics Inc., Foundation Medicine, Invitae Corporation, Guardant Health Inc., Caris Life Sciences, Fulgent Genetics, NanoString Technologies Inc., Genecast Biotechnology Co. Ltd, Burning Rock DX, HTG Molecular Diagnostics Inc., Predictive Oncology Inc.

Get The Full Genomic Cancer Panel And Profiling Market Report:

https://www.thebusinessresearchcompany.com/report/genomic-cancer-panel-and-profiling-global-market-report

Where Is The Genomic Cancer Panel And Profiling Market Primarily Concentrated By Region?

North America was the largest region in the genomic cancer panel and profiling market in 2025. The regions covered in the genomic cancer panel and profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Genomic Cancer Panel And Profiling Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/genomic-cancer-panel-and-profiling-global-market-report

Browse Through More Reports Similar to the Global Genomic Cancer Panel And Profiling Market 2026, By The Business Research Company

Cancer Profiling Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

Genomics In Cancer Care Market Report 2026

https://www.thebusinessresearchcompany.com/report/genomics-in-cancer-care-global-market-report

Cancer Tumor Profiling Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Genomic Cancer Panel And Profiling Market Over The Period 2026–2030?

The genomic cancer panel and profiling market has experienced substantial growth in recent years. This market is expected to expand from $10.28 billion in 2025 to $11.17 billion by 2026, achieving a compound annual growth rate (CAGR) of 8.7%. Historically, this growth has been fueled by factors such as the rising incidence of cancer, advancements in sequencing technologies, the broader availability of oncology diagnostics, increased financial support for genomic research, and the growing integration of precision medicine.

The genomic cancer panel and profiling market is anticipated to experience robust expansion over the coming years. This market is projected to reach $15.45 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.4%. Factors contributing to this growth during the forecast period include the broadening of companion diagnostics, increased uptake of liquid biopsy, the incorporation of AI into genomic analysis, a rise in oncology screening initiatives, and the creation of economical sequencing platforms. Key trends for the forecast duration encompass the growing acceptance of multi-gene cancer panels, an uptick in the utilization of next-generation sequencing, the widening application of liquid biopsy testing, an escalating need for personalized oncology solutions, and the incorporation of genomic data into clinical decision-making processes.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24225&type=smp

What Drivers Are Expected To Influence The Genomic Cancer Panel And Profiling Market During The Forecast Period?

The genomic cancer panel and profiling market is anticipated to expand significantly due to the increasing incidence of cancer. Cancer is fundamentally a disease marked by the uncontrolled multiplication and spread of abnormal cells within the body. This surge in cancer cases is attributable to an aging global population, where extended life expectancies naturally heighten the probability of developing the disease. Genomic cancer panels and profiling are instrumental in oncology care, as they enable the identification of genetic mutations and biomarkers, thereby facilitating personalized treatment strategies and improving both early detection and continuous monitoring. For instance, in January 2024, information from the American Cancer Society, a U.S.-based nonprofit, revealed that approximately 20 million new cancer cases were reported worldwide in 2022, resulting in 9.7 million deaths. Primarily driven by population growth, the global cancer burden is projected to climb to 35 million cases by 2050. Consequently, the rising number of cancer cases will fuel the growth of the genomic cancer panel and profiling market.

How Is The Genomic Cancer Panel And Profiling Market Divided Into Its Major Segments?

The genomic cancer panel and profiling market covered in this report is segmented –

1) By Tissue Testing: Solid Tissue Testing, Liquid Tissue Testing

2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Other Technologies

3) By Cancer Panel Type: Single-Gene Panel, Multi-Gene Panel

4) By Application: Clinical, Research

5) By End User: Hospitals, Research And Academic Institutes, Clinical And Diagnostic Laboratories, Other End Users

Subsegments:

1) By Solid Tissue Testing: Biopsy Samples, Surgical Resection Samples, Formalin-Fixed Paraffin-Embedded (FFPE) Tissues, Fresh Frozen Tissues

2) By Liquid Tissue Testing: Blood, Urine, Saliva, Cerebrospinal Fluid (CSF), Other Bodily Fluids

How Are Trends Transforming The Genomic Cancer Panel And Profiling Market Landscape?

Major companies operating within the genomic cancer panel and profiling market are prioritizing technological improvements, such as next-generation sequencers, to enhance the precision, rapidity, and thoroughness of cancer diagnostics, enabling more individualized treatment choices. Next-generation sequencers are advanced DNA sequencing technologies that facilitate swift, high-throughput examination of genetic material to pinpoint mutations, variations, and other genomic attributes. For example, in April 2025, QIAGEN N.V., a biotechnology company based in the Netherlands, launched its QIAseq panels, which are designed for next-generation sequencers and permit comprehensive genomic profiling by analyzing over 700 genes. These panels are intended for both research and clinical applications, with the goal of improving cancer diagnostics and treatment approaches.

Who Are The Prominent Organizations Shaping The Genomic Cancer Panel And Profiling Market?

Major companies operating in the genomic cancer panel and profiling market are Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Hologic Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, ARUP Laboratories, Tempus Labs, Genscript Biotech Corporation, NeoGenomics Inc., Foundation Medicine, Invitae Corporation, Guardant Health Inc., Caris Life Sciences, Fulgent Genetics, NanoString Technologies Inc., Genecast Biotechnology Co. Ltd, Burning Rock DX, HTG Molecular Diagnostics Inc., Predictive Oncology Inc.

Read the full genomic cancer panel and profiling market report here:

https://www.thebusinessresearchcompany.com/report/genomic-cancer-panel-and-profiling-global-market-report

Which Region Is Forecast To Lead The Genomic Cancer Panel And Profiling Market In Terms Of Market Size?

North America was the largest region in the genomic cancer panel and profiling market in 2025. The regions covered in the genomic cancer panel and profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Genomic Cancer Panel And Profiling Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24225&type=smp

Browse Through More Reports Similar to the Global Genomic Cancer Panel And Profiling Market 2026, By The Business Research Company

Cancer Profiling Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

Genomics In Cancer Care Market Report 2026

https://www.thebusinessresearchcompany.com/report/genomics-in-cancer-care-global-market-report

Cancer Tumor Profiling Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the genomic cancer panel and profiling market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Genomic Cancer Panel And Profiling Market between 2026 and 2030?

The genomic cancer panel and profiling market size has shown substantial expansion in recent years. It is anticipated to grow from $10.28 billion in 2025 to $11.17 billion in 2026, at a compound annual growth rate (CAGR) of 8.7%. This growth observed in the past can be ascribed to factors such as the rise in cancer prevalence, advancements in sequencing technologies, the expansion of oncology diagnostics, increased funding dedicated to genomic research, and the increasing adoption of precision medicine.

The genomic cancer panel and profiling market is forecast to undergo significant expansion in the upcoming years. Its valuation is expected to climb to $15.45 billion by 2030, demonstrating a compound annual growth rate of 8.4%. This projected growth during the forecast period is primarily driven by the widening application of companion diagnostics, an increase in liquid biopsy adoption, the incorporation of AI into genomic analysis, expanding oncology screening programs, and the creation of cost-effective sequencing platforms. Noteworthy trends anticipated in this period encompass a rise in the use of multi-gene cancer panels, increasing reliance on next-generation sequencing, the broadened availability of liquid biopsy testing, a growing need for personalized oncology treatments, and the integration of genomic data into clinical decision-making.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24225&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Genomic Cancer Panel And Profiling Market?

The escalating incidence of cancer is projected to propel the expansion of the genomic cancer panel and profiling market in the future. Cancer is a condition marked by the uncontrolled multiplication and spread of abnormal cells within the body. The uptick in cancer cases stems from an aging population, which heightens the probability of cancer development as life expectancy continues to rise. Genomic cancer panels and profiling contribute to oncology care by identifying genetic mutations and biomarkers, enabling personalized treatment plans, and improving early detection and monitoring. For instance, in January 2024, the American Cancer Society, a U.S.-based nonprofit organization, reported that in 2022, approximately 20 million new cancer cases occurred globally, resulting in 9.7 million deaths; primarily driven by population growth, the worldwide cancer burden is anticipated to reach 35 million cases by 2050. Therefore, the increasing cancer incidence will fuel the growth of the genomic cancer panel and profiling market.

What Segments Are Included Within The Genomic Cancer Panel And Profiling Market?

The genomic cancer panel and profiling market covered in this report is segmented –

1) By Tissue Testing: Solid Tissue Testing, Liquid Tissue Testing

2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Other Technologies

3) By Cancer Panel Type: Single-Gene Panel, Multi-Gene Panel

4) By Application: Clinical, Research

5) By End User: Hospitals, Research And Academic Institutes, Clinical And Diagnostic Laboratories, Other End Users

Subsegments:

1) By Solid Tissue Testing: Biopsy Samples, Surgical Resection Samples, Formalin-Fixed Paraffin-Embedded (FFPE) Tissues, Fresh Frozen Tissues

2) By Liquid Tissue Testing: Blood, Urine, Saliva, Cerebrospinal Fluid (CSF), Other Bodily Fluids

How Are New Market Trends Shaping The Landscape Of The Genomic Cancer Panel And Profiling Market?

Leading companies active in the genomic cancer panel and profiling market are emphasizing technological advancements, such as next-generation sequencing devices, to enhance the accuracy, speed, and overall scope of cancer diagnostics and to enable more tailored treatment decisions. Next-generation sequencers are sophisticated DNA sequencing technologies that facilitate rapid, high-throughput analysis of genetic material to identify mutations, variations, and other genomic characteristics. For instance, in April 2025, QIAGEN N.V., a biotechnology firm located in the Netherlands, introduced QIAseq panels specifically designed for next-generation sequencers, allowing for comprehensive genomic profiling by analyzing over 700 genes. These panels are intended for both research and clinical applications, with the aim of improving cancer diagnostics and treatment strategies.

Who Are The Core Companies Influencing Trends In The Genomic Cancer Panel And Profiling Market?

Major companies operating in the genomic cancer panel and profiling market are Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Hologic Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, ARUP Laboratories, Tempus Labs, Genscript Biotech Corporation, NeoGenomics Inc., Foundation Medicine, Invitae Corporation, Guardant Health Inc., Caris Life Sciences, Fulgent Genetics, NanoString Technologies Inc., Genecast Biotechnology Co. Ltd, Burning Rock DX, HTG Molecular Diagnostics Inc., Predictive Oncology Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/genomic-cancer-panel-and-profiling-global-market-report

Which Regions Are Projected To Dominate The Genomic Cancer Panel And Profiling Market In The Coming Years?

North America was the largest region in the genomic cancer panel and profiling market in 2025. The regions covered in the genomic cancer panel and profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Genomic Cancer Panel And Profiling Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24225&type=smp

Browse Through More Reports Similar to the Global Genomic Cancer Panel And Profiling Market 2026, By The Business Research Company

Cancer Profiling Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

Genomics In Cancer Care Market Report 2026

https://www.thebusinessresearchcompany.com/report/genomics-in-cancer-care-global-market-report

Cancer Tumor Profiling Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the genomic cancer panel and profiling market from 2025–2034 with trusted insights from The Business Research Company

How Much Will The Genomic Cancer Panel And Profiling Market Be Worth By 2029, And What CAGR Will It Achieve?

The genomic cancer panel and profiling market has experienced substantial growth in recent years. This market is anticipated to expand from $9.47 billion in 2024 to $10.28 billion in 2025, maintaining an 8.6% compound annual growth rate (CAGR). Factors contributing to its historical growth include an escalating global cancer burden, increased application in clinical trials, the expansion of diagnostic infrastructure, growing awareness surrounding genetic testing, and a rise in government and research funding.

The genomic cancer panel and profiling market size is anticipated to experience substantial growth in the coming years, with projections indicating it will reach $14.27 billion by 2029, growing at a compound annual growth rate (CAGR) of 8.5%. This expansion during the forecast period is primarily driven by the increasing application of liquid biopsy, its rising utilization in early detection, advancements in tailored therapies, and a growing number of companion diagnostics approvals. Key trends expected in this period include the integration of artificial intelligence and machine learning in genomic data interpretation, the development of multi-omics approaches, the adoption of cloud-based genomic data storage and analysis, integration with electronic health records, and the broader implementation of next-generation sequencing (NGS) platforms.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24225&type=smp

Which Factors Are Driving The Genomic Cancer Panel And Profiling Market Forward?

The increasing occurrence of cancer is anticipated to fuel the expansion of the genomic cancer panel and profiling market in the future. Cancer is a condition marked by the unchecked growth and spread of abnormal cells within the body. The rise in cancer incidence can be linked to elements like an aging population, as longer lifespans contribute to a greater risk of developing the disease. Genomic cancer panels and profiling are utilized in cancer treatment to identify genetic mutations and biomarkers, thereby enabling personalized treatment plans and improving early detection and monitoring of the illness. For instance, in January 2024, the American Cancer Society, a U.S.-based nonprofit organization, reported that in 2022, roughly 20 million new cancer cases were recorded globally, resulting in 9.7 million deaths; primarily driven by population growth, the global cancer burden is projected to increase to 35 million cases by 2050. Therefore, the growing incidence of cancer is set to propel the genomic cancer panel and profiling market forward.

Which Segments Form The Key Structure Of The Genomic Cancer Panel And Profiling Market?

The genomic cancer panel and profiling market covered in this report is segmented –

1) By Tissue Testing: Solid Tissue Testing, Liquid Tissue Testing

2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Other Technologies

3) By Cancer Panel Type: Single-Gene Panel, Multi-Gene Panel

4) By Application: Clinical, Research

5) By End User: Hospitals, Research And Academic Institutes, Clinical And Diagnostic Laboratories, Other End Users

Subsegments:

1) By Solid Tissue Testing: Biopsy Samples, Surgical Resection Samples, Formalin-Fixed Paraffin-Embedded (FFPE) Tissues, Fresh Frozen Tissues

2) By Liquid Tissue Testing: Blood, Urine, Saliva, Cerebrospinal Fluid (CSF), Other Bodily Fluids

What Strategic Shifts And Innovations Are Influencing The Genomic Cancer Panel And Profiling Market?

Leading firms within the genomic cancer panel and profiling market are concentrating on innovations like next-generation sequencers to elevate the precision, pace, and thoroughness of cancer diagnostics, thereby facilitating more tailored treatment choices. These sequencers represent sophisticated DNA sequencing techniques that allow for quick, large-scale examination of genetic material to pinpoint mutations, variations, and various genomic characteristics. As an illustration, in April 2025, the Netherlands-based biotechnology company QIAGEN N.V. introduced QIAseq panels, specifically developed for next-generation sequencers, which permit extensive genomic profiling through the analysis of over 700 genes. The purpose of these panels extends to both investigative studies and clinical uses, with the goal of enhancing cancer diagnostic methods and therapeutic approaches.

Which Firms Are Making The Biggest Impact In The Genomic Cancer Panel And Profiling Market?

Major companies operating in the genomic cancer panel and profiling market are Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Hologic Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, ARUP Laboratories, Tempus Labs, Genscript Biotech Corporation, NeoGenomics Inc., Foundation Medicine, Invitae Corporation, Guardant Health Inc., Caris Life Sciences, Fulgent Genetics, NanoString Technologies Inc., Genecast Biotechnology Co. Ltd, Burning Rock DX, HTG Molecular Diagnostics Inc., Predictive Oncology Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/genomic-cancer-panel-and-profiling-global-market-report

Which Region Is Expected To Lead The Genomic Cancer Panel And Profiling Market In The Next Few Years?

North America was the largest region in the genomic cancer panel and profiling market in 2024. The regions covered in the genomic cancer panel and profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=24225&type=smp

Browse Through More Reports Similar to the Global Genomic Cancer Panel And Profiling Market 2025, By The Business Research Company

Genomics In Cancer Care Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genomics-in-cancer-care-global-market-report

Urothelial Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/urothelial-cancer-drugs-global-market-report

Ovarian Cancer Drugs Market 2025

https://www.thebusinessresearchcompany.com/report/ovarian-cancer-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Market Value Is The Genomic Cancer Panel And Profiling Industry Expected To Reach By 2029, Starting From 2025 Levels?

The genomic cancer panel and profiling market size has demonstrated significant expansion in recent years. Its valuation is projected to increase from $9.47 billion in 2024 to $10.28 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.6%. Historically, this growth can be attributed to an escalating global cancer burden, increased utilization in clinical trials, the expansion of diagnostic infrastructure, heightened awareness regarding genetic testing, and growing financial support from governments and research institutions.

The genomic cancer panel and profiling market size is anticipated to experience robust growth over the next few years, projected to reach $14.27 billion by 2029, driven by a compound annual growth rate (CAGR) of 8.5%. This expansion during the forecast period can be attributed to factors such as the increasing applications of liquid biopsy, its growing role in early detection, the rise of tailored therapies, and a greater number of companion diagnostics approvals. Prominent trends expected in this period include the integration of AI and machine learning into genomic data interpretation, the development of multi-omics approaches, cloud-based genomic data storage and analysis solutions, integration with electronic health records, and the wider deployment of next-generation sequencing (NGS) platforms.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24225&type=smp

Which Industry Drivers Are Expected To Accelerate The Genomic Cancer Panel And Profiling Market From 2025 To 2029?

The anticipated increase in cancer cases is set to propel the growth of the genomic cancer panel and profiling market. Cancer is defined as a disease marked by the uncontrolled proliferation and dissemination of abnormal cells throughout the body. The rising incidence of cancer can be linked to factors such as an aging population, which increases the likelihood of developing the disease as individuals live longer. Genomic cancer panels and profiling are utilized in oncology to pinpoint genetic mutations and biomarkers, thereby enabling tailored treatment strategies and enhancing the early detection and surveillance of the illness. For instance, in January 2024, the American Cancer Society, a U.S.-based nonprofit organization, reported that in 2022, approximately 20 million new cancer cases were recorded globally, resulting in 9.7 million deaths; primarily driven by population growth, the worldwide cancer burden is projected to reach 35 million cases by 2050. Consequently, the increasing prevalence of cancer will drive the expansion of the genomic cancer panel and profiling market.

What Are The Major Segment Categories Driving The Genomic Cancer Panel And Profiling Market Growth?

The genomic cancer panel and profiling market covered in this report is segmented –

1) By Tissue Testing: Solid Tissue Testing, Liquid Tissue Testing

2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Other Technologies

3) By Cancer Panel Type: Single-Gene Panel, Multi-Gene Panel

4) By Application: Clinical, Research

5) By End User: Hospitals, Research And Academic Institutes, Clinical And Diagnostic Laboratories, Other End Users

Subsegments:

1) By Solid Tissue Testing: Biopsy Samples, Surgical Resection Samples, Formalin-Fixed Paraffin-Embedded (FFPE) Tissues, Fresh Frozen Tissues

2) By Liquid Tissue Testing: Blood, Urine, Saliva, Cerebrospinal Fluid (CSF), Other Bodily Fluids

What Trends Are Expected To Drive The Genomic Cancer Panel And Profiling Market?

Leading companies operating in the genomic cancer panel and profiling market are increasingly focusing on technological advancements, such as next-generation sequencers, to enhance the accuracy, speed, and comprehensiveness of cancer diagnostics and facilitate more personalized treatment decisions. These next-generation sequencers are sophisticated DNA sequencing technologies that enable rapid, high-throughput analysis of genetic material to identify mutations, variations, and other genomic features. As an illustration, in April 2025, QIAGEN N.V., a biotechnology company located in the Netherlands, introduced QIAseq panels tailored for next-generation sequencers, which allow for comprehensive genomic profiling by analyzing more than 700 genes. These panels are designed for both research and clinical applications, with the objective of improving cancer diagnostics and treatment strategies.

Which Leading Players Are Enhancing Their Genomic Cancer Panel And Profiling Market Presence Worldwide?

Major companies operating in the genomic cancer panel and profiling market are Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Hologic Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, ARUP Laboratories, Tempus Labs, Genscript Biotech Corporation, NeoGenomics Inc., Foundation Medicine, Invitae Corporation, Guardant Health Inc., Caris Life Sciences, Fulgent Genetics, NanoString Technologies Inc., Genecast Biotechnology Co. Ltd, Burning Rock DX, HTG Molecular Diagnostics Inc., Predictive Oncology Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/genomic-cancer-panel-and-profiling-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Genomic Cancer Panel And Profiling Market?

North America was the largest region in the genomic cancer panel and profiling market in 2024. The regions covered in the genomic cancer panel and profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Genomic Cancer Panel And Profiling Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24225&type=smp

Browse Through More Reports Similar to the Global Genomic Cancer Panel And Profiling Market 2025, By The Business Research Company

Genomics In Cancer Care Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genomics-in-cancer-care-global-market-report

Urothelial Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/urothelial-cancer-drugs-global-market-report

Ovarian Cancer Drugs Market 2025

https://www.thebusinessresearchcompany.com/report/ovarian-cancer-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Present And Forecasted Size Of The Genomic Cancer Panel And Profiling Market?

In recent years, the market size of genomic cancer panel and profiling has seen robust growth. The market is projected to expand from a value of $9.47 billion in 2024 to $10.28 billion in 2025, registering a compound annual growth rate (CAGR) of 8.6%. The exceptional growth during the historical period can be credited to factors like escalating global cancer rates, amplified use in clinical trials, development of diagnostic infrastructure, heightened awareness regarding genetic testing, and augmented government and research funding.

There is a promising surge projected for the market size of genomic cancer panel and profiling in the coming times. The expansion is anticipated to reach “$14.27 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.5%. This growth during the projected time frame is linked to the broader implementation of liquid biopsy applications, the escalating use in early disease detection, the expansion of personalized therapies, and the rise in approvals for companion diagnostics. The forthcoming period is also expected to see major trends such as the utilization of AI and machine learning for interpreting genomic data, the birth of multi-omics methodologies, the transition to cloud-based genomic data storage and analysis, the integration with electronic medical records, and the growth of Next-Generation Sequencing (NGS) platforms.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24225&type=smp

Which Key Factors Are Fueling Growth In The Genomic Cancer Panel And Profiling Market?

Expectations are that the genomic cancer panel and profiling market will experience growth due to a surge in cancer incidences. The disorder known as cancer exhibits abnormal cell growth and spread without control in the body. The escalating cancer incidence is linked to factors like an aging populace, which increases the likelihood of cancer as people’s lifespan extends. Genomic cancer panels and profiling assist in spotting genetic mutations and biomarkers in cancer, which helps in formulating personalized treatment plans and amplifying early detection and disease monitoring. For instance, data from the American Cancer Society, a nonprofit organization based in the U.S., revealed that in 2022, an estimated 20 million new cancer cases were globally reported, causing about 9.7 million fatalities. The anticipation is that the global cancer burden, mainly propelled by population growth, will escalate to 35 million incidences by 2050. Consequently, the upsurge in cancer incidence is projected to boost the genomic cancer panel and profiling market growth.

How Is The Genomic Cancer Panel And Profiling Market Organized By Different Segments?

The genomic cancer panel and profiling market covered in this report is segmented –

1) By Tissue Testing: Solid Tissue Testing, Liquid Tissue Testing

2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Other Technologies

3) By Cancer Panel Type: Single-Gene Panel, Multi-Gene Panel

4) By Application: Clinical, Research

5) By End User: Hospitals, Research And Academic Institutes, Clinical And Diagnostic Laboratories, Other End Users

Subsegments:

1) By Solid Tissue Testing: Biopsy Samples, Surgical Resection Samples, Formalin-Fixed Paraffin-Embedded (FFPE) Tissues, Fresh Frozen Tissues

2) By Liquid Tissue Testing: Blood, Urine, Saliva, Cerebrospinal Fluid (CSF), Other Bodily Fluids

What Current And Upcoming Trends Are Shaping The Genomic Cancer Panel And Profiling Market?

Major players within the genomic cancer panel and profiling market are prioritizing the advancement of technology such as next-generation sequencers. This is in an effort to enhance the accuracy, speed, and scope of cancer diagnostics and contribute to more tailored treatment decisions. Next-generation sequencers are highly advanced DNA sequencing technologies that facilitate quick, high-throughput examinations of genetic content in order to detect mutations, variants and other genomic characteristics. For instance, QIAGEN N.V., a biotechnology company based in Netherlands, introduced QIAseq panels in April 2025, which are specially designed for next-generation sequencers. By scrutinizing over 700 genes, they offer comprehensive genomic profiling. These panels are directed at both research and clinical undertakings, with the intent of elevating the standards of cancer diagnostics and treatment approaches.

Which Firms Are Making The Biggest Impact In The Genomic Cancer Panel And Profiling Market?

Major companies operating in the genomic cancer panel and profiling market are Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Hologic Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, ARUP Laboratories, Tempus Labs, Genscript Biotech Corporation, NeoGenomics Inc., Foundation Medicine, Invitae Corporation, Guardant Health Inc., Caris Life Sciences, Fulgent Genetics, NanoString Technologies Inc., Genecast Biotechnology Co. Ltd, Burning Rock DX, HTG Molecular Diagnostics Inc., Predictive Oncology Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/genomic-cancer-panel-and-profiling-global-market-report

Which Region Dominates The Genomic Cancer Panel And Profiling Market Today?

North America was the largest region in the genomic cancer panel and profiling market in 2024. The regions covered in the genomic cancer panel and profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=24225&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Genomic Cancer Panel And Profiling Market Size Shifted, And What Is the Outlook Through 2034?

There has been a significant increase in the market size of the genomic cancer panel and profiling within recent years. The market is estimated to climb from a value of $9.47 billion in 2024 to $10.28 billion in 2025, expanding at a compound annual growth rate (CAGR) of 8.6%. Factors like the growing global incidence of cancer, its growing use in clinical trials, the widening diagnostic infrastructure, growing knowledge about genetic testing, and an uptick in government-backed and research funding have contributed to the growth observed in the historic period.

The market size of genomic cancer panel and profiling is anticipated to have sturdy growth over the upcoming years. The estimated growth will reach $14.27 billion by 2029, with a compound annual growth rate (CAGR) of 8.5%. Factors contributing to this growth during the projection phase include increasing applications of liquid biopsy, growing utilization in early detection, the rise of personalized therapies, and an upswing in companion diagnostics approvals. Key trends during this period involve merging of AI and machine learning for interpreting genomic data, progress in multi-omics approaches, genomic data storage and analysis via the cloud, integration with electronic health records, and extension of next-generation sequencing (NGS) platforms.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24225&type=smp

What are the Fundamental Drivers and Innovations Shaping the Genomic Cancer Panel And Profiling Market?

The escalating occurrence of cancer is estimated to accelerate the expansion of the genomic cancer panel and profiling market. Recognized by the rapid and unregulated proliferation and dissemination of abnormal cells within the body, cancer is a malady whose increasing prevalence can be attributed to aspects like an aging population, which in turn intensifies the chances of cancer development due to a longer lifespan. Genomic cancer panels and profiling come into play in oncology to detect genetic variances and biomarkers, thus facilitating tailor-made treatment regimens while enhancing early cancer detection and its surveillance. For instance, the American Cancer Society, a non-profit organization based in the U.S., reported in January 2024 that approximately 20 million new instances of cancer had been globally reported in 2022, which resulted in about 9.7 million fatalities. These figures are primarily driven by population growth and the global burden of cancer is forecasted to escalate to 35 million cases by 2050. Consequently, the increasing incidence of cancer will fuel the expansion of the genomic cancer panel and profiling market.

How Is the Genomic Cancer Panel And Profiling Market Segmented?

The genomic cancer panel and profiling market covered in this report is segmented –

1) By Tissue Testing: Solid Tissue Testing, Liquid Tissue Testing

2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Other Technologies

3) By Cancer Panel Type: Single-Gene Panel, Multi-Gene Panel

4) By Application: Clinical, Research

5) By End User: Hospitals, Research And Academic Institutes, Clinical And Diagnostic Laboratories, Other End Users

Subsegments:

1) By Solid Tissue Testing: Biopsy Samples, Surgical Resection Samples, Formalin-Fixed Paraffin-Embedded (FFPE) Tissues, Fresh Frozen Tissues

2) By Liquid Tissue Testing: Blood, Urine, Saliva, Cerebrospinal Fluid (CSF), Other Bodily Fluids

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=24225&type=smp

Which Regions Are Driving the Next Phase of the Genomic Cancer Panel And Profiling Market Growth?

North America was the largest region in the genomic cancer panel and profiling market in 2024. The regions covered in the genomic cancer panel and profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Trends Are Shaping the Future of the Genomic Cancer Panel And Profiling Market?

Major corporations in the genomic cancer panel and profiling industry are concentrating their resources on innovative developments like next-generation sequencers in order to enhance the precision, velocity, and inclusivity of cancer diagnostics while supporting more personalized approaches to treatment. Next-generation sequencers are cutting-edge DNA sequencing technologies that expedite exhaustive analysis of genetic matter to pinpoint mutations, variances, and other genomic characteristics. For instance, QIAGEN N.V., a biotech company out of the Netherlands, introduced its QIAseq panels specifically configured for next-generation sequencers in April 2025. These panels can efficiently scrutinize over 700 genes, with applications in both research and clinical fields, aiming to revolutionize cancer diagnostics and treatment approaches.

View the full report here:

https://www.thebusinessresearchcompany.com/report/genomic-cancer-panel-and-profiling-global-market-report

How Is the Genomic Cancer Panel And Profiling Market Defined and What Are Its Core Parameters?

Genomic cancer panel and profiling is a molecular diagnostic technique that analyzes multiple genes simultaneously to detect genetic mutations, alterations, or biomarkers associated with cancer. Its primary purpose is to guide personalized treatment decisions, predict disease progression, and improve cancer diagnosis and monitoring.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24225

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model